| Literature DB >> 24198811 |
Dorian S Houser1, Cory D Champagne, Daniel E Crocker.
Abstract
Insulin resistance in modern society is perceived as a pathological consequence of excess energy consumption and reduced physical activity. Its presence in relation to the development of cardiovascular risk factors has been termed the metabolic syndrome, which produces increased mortality and morbidity and which is rapidly increasing in human populations. Ironically, insulin resistance likely evolved to assist animals during food shortages by increasing the availability of endogenous lipid for catabolism while protecting protein from use in gluconeogenesis and eventual oxidation. Some species that incorporate fasting as a predictable component of their life history demonstrate physiological traits similar to the metabolic syndrome during prolonged fasts. One such species is the northern elephant seal (Mirounga angustirostris), which fasts from food and water for periods of up to 4 months. During this time, ∼90% of the seals metabolic demands are met through fat oxidation and circulating non-esterified fatty acids are high (0.7-3.2 mM). All life history stages of elephant seal studied to date demonstrate insulin resistance and fasting hyperglycemia as well as variations in hormones and adipocytokines that reflect the metabolic syndrome to some degree. Elephant seals demonstrate some intriguing adaptations with the potential for medical advancement; for example, ketosis is negligible despite significant and prolonged fatty acid oxidation and investigation of this feature might provide insight into the treatment of diabetic ketoacidosis. The parallels to the metabolic syndrome are likely reflected to varying degrees in other marine mammals, most of which evolved on diets high in lipid and protein content but essentially devoid of carbohydrate. Utilization of these natural models of insulin resistance may further our understanding of the pathophysiology of the metabolic syndrome in humans and better assist the development of preventative measures and therapies.Entities:
Keywords: elephant seal; fasting; hyperglycemia; insulin resistance; metabolic syndrome
Year: 2013 PMID: 24198811 PMCID: PMC3814516 DOI: 10.3389/fendo.2013.00164
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Summary information of metabolites and glucoregulatory hormones studied in the different life history stages of the northern elephant seal.
| Class | Glucose (mM) | Lactate (mM) | BUN (mg/dL) | NEFA (mM) | Glycerol (μM) | BHB (μM) | AcAc (μM) | Insulin (pg/mL) | Insulin (pM) | Glucagon (pg/mL) | Glucagon (pM) | I:G | Cortisol (ng/mL) | Cortisol (nM) | EGP (mmol/min) | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early lactation | 7.0 (0.7) | 2.4 (0.3) | 189 (49) | 264 (24) | 101.8 (16.9) | 17.5 (2.9) | 43.1 (11.4) | 12.4 (3.3) | 1.5 (0.5) | 53.5 (19.6) | 147.7 (54.1) | 3.9 (0.7) | Champagne et al. ( | |||
| Early lactation | 7.4 (0.5) | 2.5 (0.8) | 1.0 (0.2) | 250 (60) | 700 (230) | 98.2 (20.3) | 16.9 (3.5) | 57.1 (18.5) | 16.4 (5.3) | 1.0 (–) | 52.2 (24.8) | 144.2 (68.4) | Houser et al. ( | |||
| Early lactation | 7.0 (0.2) | 83.3 (8.8) | 14.3 (1.5) | 29.8 (2.1) | 8.4 (0.6) | 1.7 (0.2) | Fowler et al. ( | |||||||||
| Early lactation | 7.6 (0.5) | 2.4 (0.8) | 67.4 (15.1) | 11.6 (2.6) | 37.3 (13.2) | 10.7 (3.8) | 1.2 (0.4) | 56.9 (12.0) | 157 (33) | Champagne et al. ( | ||||||
| Late lactation | 8.2 (0.7) | 2.5 (0.4) | 462 (171) | 345 (40) | 68.8 (11.6) | 11.8 (2.0) | 38.8 (11.4) | 11.1 (3.3) | 1.2 (0.4) | 103.5 (29.9) | 285.7 (82.5) | 3.3 (0.8) | Champagne et al. ( | |||
| Late lactation | 7.2 (1.0) | 2.7 (0.7) | 3.2 (0.8) | 520 (220) | 760 (210) | 76.7 (18.0) | 13.2 (3.1) | 54.3 (13.2) | 15.6 (3.8) | 0.9 (–) | 89.4 (30.1) | 246.8 (83.2) | Houser et al. ( | |||
| Late lactation | 6.8 (0.5) | 43.0 (10.1) | 7.4 (1.7) | 36.6 (5.5) | 10.5 (1.6) | 0.7 (0.1) | Fowler et al. ( | |||||||||
| Late lactation | 7.7 (0.6) | 2.4 (0.8) | 58.7 (23.8) | 10.1 (4.1) | 41.1 (10.8) | 11.8 (3.1) | 0.9 (0.3) | 71.4 (17.8) | 197 (49) | Champagne et al. ( | ||||||
| Post-molt | 7.1 (0.6) | 3.8 (0.8) | 204 (82) | 288 (52) | 87.0 (18.1) | 15.0 (3.1) | 46.5 (13.4) | 13.4 (3.8) | 1.2 (0.3) | 80.8 (20.7) | 223.0 (57.1) | Champagne et al. ( | ||||
| Post-molt | 6.2 (0.2) | 3.7 (1.0) | 1.4 (0.3) | 340 (80) | 630 (80) | 86.0 (15.7) | 14.8 (2.7) | 46.7 (8.0) | 13.4 (2.3) | 1.1 (–) | 107.2 (66.9) | 295.8 (184.6) | Houser et al. ( | |||
| Post-molt | 7.0 (0.3) | 84.2 (5.5) | 14.5 (0.9) | Fowler et al. ( | ||||||||||||
| Early fasting | 6.0 (0.3) | 10.2 (0.3) | 0.8 (0.1) | 234 (11) | 73.9 (3.5) | 12.7 (0.6) | 35.9 (3.5) | 10.3 (1.0) | 1.3 (0.1) | 83 (7) | 229.1 (19.3) | Crocker et al. ( | ||||
| Late fasting | 5.5 (0.4) | 10.5 (0.3) | 0.8 (0.6) | 365 (12) | 68.3 (2.0) | 11.8 (0.3) | 49.9 (2.9) | 14.3 (0.8) | 0.8 (0.1) | 77 (9) | 212.5 (24.8) | Crocker et al. ( | ||||
| Early fasting | 28.9 (11.5) | 49 (17) | 135.2 (46.9) | Houser et al. ( | ||||||||||||
| Early fasting | 8.6 (0.9) | 67.6 (10.5) | 11.6 (1.8) | 51.6 (14.0) | 14.8 (4.0) | 0.8 (0.2) | 53.3 (26.1) | 147.1 (72.0) | 1.6 (0.1) | Champagne et al. ( | ||||||
| Early fasting | 8.9 (1.1) | 3.1 (0.7) | 423 (87) | Tavoni et al. ( | ||||||||||||
| Early fasting | 8.6 (0.3) | 2.5 (0.4) | 477 (100) | 129 (7) | 77.8 (21.5) | 13.4 (3.7) | 28.9 (4.9) | 8.3 (1.4) | 1.6 (–) | 64.31 (10.4) | 177.5 (28.7) | 1.4 (0.3) | Houser et al. ( | |||
| Early fasting | 7.8 (0.6) | 3.7 (0.9) | 62.1 (43.6) | 10.7 (7.5) | 69.3 (15.0) | 19.9 (4.3) | 0.5 (0.4) | 63.4 (23.9) | 175 (66) | Champagne et al. ( | ||||||
| Early fasting | 9.7 (0.8) | 3.0 (0.8) | 56.6 (10.4) | 61.6 (13.4) | 10.6 (2.3) | 44.6 (9.1) | 12.8 (2.6) | 0.9 (0.3) | 564 (238) | 1.8 (0.3) | Champagne et al. ( | |||||
| Early fasting | 9.6 (0.7) | 0.9 (0.1) | 180 (10) | 87.1 (10.5) | 15.0 (1.8) | 95.7 (12.7) | 264 (35) | Viscarra et al. ( | ||||||||
| Early fasting | 9.8 (0.5) | 0.7 (0.0) | 94.1 (13.9) | 16.2 (2.4) | 44.9 (2.2) | 124 (6) | Viscarra et al. ( | |||||||||
| Early fasting | ||||||||||||||||
| Late fasting | 19.5 (15.6) | 98 (63) | 270.5 (173.9) | Houser et al. ( | ||||||||||||
| Late fasting | 8.0 (0.5) | 57.1 (13.6) | 9.8 (2.3) | 69.4 (17.0) | 19.9 (4.9) | 0.5 (0.2) | 61.3 (22.7) | 169.2 (62.7) | 1.1 (0.0) | Champagne et al. ( | ||||||
| Late fasting | 8.5 (1.4) | 1.8 (0.6) | 997 (169) | 170 (16) | 53.4 (19.7) | 9.2 (3.4) | 24.4 (4.5) | 7.0 (1.3) | 1.3 (–) | 65.5 (12.0) | 180.7 (33.2) | 1.0 (0.2) | Houser et al. ( | |||
| Late fasting | 7.5 (0.3) | 3.0 (0.8) | 45.9 (16.3) | 7.9 (2.8) | 68.3 (12.5) | 19.5 (3.6) | 0.5 (0.2) | 78.6 (27.2) | 217 (75) | Champagne et al. ( | ||||||
| Late fasting | 10.3 (0.8) | 2.2 (0.8) | 128.6 (19.3) | 35.4 (15.1) | 6.1 (2.6) | 58.5 (19.2) | 16.8 (5.5) | 0.4 (0.1) | 788 (419) | 1.2 (0.2) | Champagne et al. ( | |||||
| Late fasting | 7.1 (0.5) | 1.6 (0.2) | 240 (10) | 41.8 (3.5) | 7.2 (0.6) | 172.8 (17.8) | 477 (49) | Viscarra et al. ( | ||||||||
| Late fasting | 8.0 (0.3) | 0.9 (0.1) | 34.8 (3.5) | 6.0 (0.6) | 93.1 (10.9) | 257 (30) | Viscarra et al. ( | |||||||||
BUN, blood urea nitrogen; NEFA, non-esterified fatty acids; BHB, beta-hydroxybutyrate; AcAc, acetoacetate; I:G, insulin to glucagon ratio; EGP, endogenous glucose production.
.
Figure 1A comparison of endogenous glucose production between fasting seals and other terrestrial mammals. Terrestrial mammals are separated as those that are post-absorptive (open squares) and those that have been fasting for 24 or more hours (filled squares). Elephant seals are separated according to whether measurements were made during the early or late fasting period (see text for details on fasting duration as a function of life history stage).
Figure 2Variations in metabolic pathways with time fasting that contribute to insulin resistance in the northern elephant seals. The model draws upon findings from multiple age classes and likely demonstrates age and gender-specific variations. Dashed lines indicate reductions in metabolite or hormone production, bold lines indicate increased production, and normally weighted lines indicate no change. Arrows next to a metabolite or hormone indicate either increased levels (upward arrow) or decreased levels (downward arrow). (EGP, endogenous glucose production; NEFA, non-esterified fatty acids; TNF-α, tumor necrosis factor alpha; IRS-1, phosphorylated form of insulin receptor substrate; IR, phosphorylated form of insulin receptor; Akt2, expression of the Akt2 gene; Glut-4, expression of the plasma membrane glucose transporter 4.)